Džodić, Predrag

Link to this page

Authority KeyName Variants
6e7cb72d-2a8c-483c-9c28-5209f3ea1c85
  • Džodić, Predrag (4)
Projects

Author's Bibliography

Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine

Jovanović, Aleksandar; Kundalić, Ana; Miladinović, Bojana; Džodić, Predrag; Catić-Đorđević, Aleksandra; Krajnović, Dušanka; Tadić, Ivana

(Savez farmaceutskih udruženja Srbije, 2023)

TY  - CONF
AU  - Jovanović, Aleksandar
AU  - Kundalić, Ana
AU  - Miladinović, Bojana
AU  - Džodić, Predrag
AU  - Catić-Đorđević, Aleksandra
AU  - Krajnović, Dušanka
AU  - Tadić, Ivana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5352
AB  - Kao jedan od najvećih javnozdravstvenih izazova diabetes mellitus predstavlja razlog
konstantnog unapređenja farmakoterapije (1). Savremena terapija diabetes mellitus-a može
promeniti tok bolesti, prevenirati komplikacije i doprineti uštedi u zdravstvu (2). Cilj rada bio je da
se analizira potrošnja antidijabetika u Srbiji, u periodu od 2012. do 2021. godine i usklađenost sa
preporukama Nacionalnog vodiča. Podaci o potrošnji antidijabetika prikupljeni su iz publikacija
Agencije za lekove i medicinska sredstva Srbije. Za svaki internacionalni nezaštićen naziv (INN),
praćena je potrošnja izražena u standardizovanoj jedinici - definisanoj dnevnoj dozi na 1000
stanovnika u danu (DDD/1000 stanovnika/dan). Najveća potrošnja antidijabetika tokom ispitivanog
perioda primećena je 2020. godine, dok je najniža bila 2012. godine. Potrošnja antidijabetika u 2021.
godini iznosila je 92,18 DDD/1000 stanovnika/dan što je za 23,73% više u odnosu na 2012. godinu.
Među ovom grupom lekova dominira upotreba oralnih antidijabetika koji se u proseku primenjuju
4,45 puta više u odnosu na insulin i analoge. Najzastupljeniji lekovi u ukupnoj potrošnji antidijabetika
do 2017. godine bili su sulfonamidi i derivati sulfonilureje kada su u proseku činili 43,39%. Nakon
2017. godine prvo mesto po potrošnji zauzima metformin, čiji udeo u ukupnoj potrošnji
antidijabetika dostiže 48,75% u 2021. godini. Potrošnja novih oralnih antidijabetika je veoma mala i
ne prelazi 0,1% ukupne potrošnje tokom ispitivanog perioda. Ipak najveći porast je primećen u
upotrebi inhibitora natrijum-glukoznog kotransportera 2 (SGLT2) (3,19 DDD/1000 stanovnika/dan
u 2021. godini nasuprot 0,001 DDD/1000 stanovnika/dan u 2015. godini). Rastući trend potrošnje
posebno je izražen kod metformina i SGLT2 inhibitora. Rezultati ukazuju na usklađenost primene
antidijabetika sa preporukama Nacionalnog vodiča.
AB  - As one of the biggest public health challenges, diabetes mellitus represents the reason for the
constant pharmacotherapy improvement (1). Modern therapy of diabetes mellitus can alter the
course of the disease, prevent complications, and contribute to healthcare savings (2). This study
aimed to analyze the consumption of antidiabetic drugs in the Republic of Serbia from 2012 to 2021
and compliance with the recommendations of the National Guide. The consumption of all registered
antidiabetic drugs was obtained from publications of the Medicines and Medical Devices Agency of
Serbia. For each International Nonproprietary Name (INN), consumption was monitored and
expressed in a standardized unit-defined daily dose per 1000 inhabitants per day (DDD/1000
inhabitants/day). During the study period, the highest consumption was observed in 2020, while the
lowest was in 2012. Antidiabetic drug consumption in 2021 amounted to 92.18 DDD/1000
inhabitants/day, which is 23.73% higher compared to 2012. The consumption of oral antidiabetics
was dominant, on average 4.45 times more than insulin and analogs. The most commonly used drugs
until 2017 in total antidiabetic consumption were sulfonylureas and sulfonylurea derivatives,
constituting an average of 43.39%. After 2017, metformin took the lead in consumption, reaching
48.75% of total antidiabetic consumption in 2021. New oral antidiabetic drugs do not exceed 0.1%
of the total consumption during the examined period. However, sodium-glucose cotransporter-2
(SGLT2) inhibitors (3.19 DDD/1000 inhabitants/day in 2021 compared to 0.001 DDD/1000
inhabitants/day in 2015) noted the most significant increase. The increasing consumption trend is
particularly pronounced for metformin and SGLT2 inhibitors. The results indicate compliance in the
use of antidiabetic drugs with the National Guide recommendations.
PB  - Savez farmaceutskih udruženja Srbije
C3  - Arhiv za farmaciju
T1  - Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine
T1  - Diabetes in Serbia: trends in antidiabetic drug consumption from 2012 to 2021
VL  - 73
IS  - Suppl. 4
SP  - S51
EP  - S52
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5352
ER  - 
@conference{
author = "Jovanović, Aleksandar and Kundalić, Ana and Miladinović, Bojana and Džodić, Predrag and Catić-Đorđević, Aleksandra and Krajnović, Dušanka and Tadić, Ivana",
year = "2023",
abstract = "Kao jedan od najvećih javnozdravstvenih izazova diabetes mellitus predstavlja razlog
konstantnog unapređenja farmakoterapije (1). Savremena terapija diabetes mellitus-a može
promeniti tok bolesti, prevenirati komplikacije i doprineti uštedi u zdravstvu (2). Cilj rada bio je da
se analizira potrošnja antidijabetika u Srbiji, u periodu od 2012. do 2021. godine i usklađenost sa
preporukama Nacionalnog vodiča. Podaci o potrošnji antidijabetika prikupljeni su iz publikacija
Agencije za lekove i medicinska sredstva Srbije. Za svaki internacionalni nezaštićen naziv (INN),
praćena je potrošnja izražena u standardizovanoj jedinici - definisanoj dnevnoj dozi na 1000
stanovnika u danu (DDD/1000 stanovnika/dan). Najveća potrošnja antidijabetika tokom ispitivanog
perioda primećena je 2020. godine, dok je najniža bila 2012. godine. Potrošnja antidijabetika u 2021.
godini iznosila je 92,18 DDD/1000 stanovnika/dan što je za 23,73% više u odnosu na 2012. godinu.
Među ovom grupom lekova dominira upotreba oralnih antidijabetika koji se u proseku primenjuju
4,45 puta više u odnosu na insulin i analoge. Najzastupljeniji lekovi u ukupnoj potrošnji antidijabetika
do 2017. godine bili su sulfonamidi i derivati sulfonilureje kada su u proseku činili 43,39%. Nakon
2017. godine prvo mesto po potrošnji zauzima metformin, čiji udeo u ukupnoj potrošnji
antidijabetika dostiže 48,75% u 2021. godini. Potrošnja novih oralnih antidijabetika je veoma mala i
ne prelazi 0,1% ukupne potrošnje tokom ispitivanog perioda. Ipak najveći porast je primećen u
upotrebi inhibitora natrijum-glukoznog kotransportera 2 (SGLT2) (3,19 DDD/1000 stanovnika/dan
u 2021. godini nasuprot 0,001 DDD/1000 stanovnika/dan u 2015. godini). Rastući trend potrošnje
posebno je izražen kod metformina i SGLT2 inhibitora. Rezultati ukazuju na usklađenost primene
antidijabetika sa preporukama Nacionalnog vodiča., As one of the biggest public health challenges, diabetes mellitus represents the reason for the
constant pharmacotherapy improvement (1). Modern therapy of diabetes mellitus can alter the
course of the disease, prevent complications, and contribute to healthcare savings (2). This study
aimed to analyze the consumption of antidiabetic drugs in the Republic of Serbia from 2012 to 2021
and compliance with the recommendations of the National Guide. The consumption of all registered
antidiabetic drugs was obtained from publications of the Medicines and Medical Devices Agency of
Serbia. For each International Nonproprietary Name (INN), consumption was monitored and
expressed in a standardized unit-defined daily dose per 1000 inhabitants per day (DDD/1000
inhabitants/day). During the study period, the highest consumption was observed in 2020, while the
lowest was in 2012. Antidiabetic drug consumption in 2021 amounted to 92.18 DDD/1000
inhabitants/day, which is 23.73% higher compared to 2012. The consumption of oral antidiabetics
was dominant, on average 4.45 times more than insulin and analogs. The most commonly used drugs
until 2017 in total antidiabetic consumption were sulfonylureas and sulfonylurea derivatives,
constituting an average of 43.39%. After 2017, metformin took the lead in consumption, reaching
48.75% of total antidiabetic consumption in 2021. New oral antidiabetic drugs do not exceed 0.1%
of the total consumption during the examined period. However, sodium-glucose cotransporter-2
(SGLT2) inhibitors (3.19 DDD/1000 inhabitants/day in 2021 compared to 0.001 DDD/1000
inhabitants/day in 2015) noted the most significant increase. The increasing consumption trend is
particularly pronounced for metformin and SGLT2 inhibitors. The results indicate compliance in the
use of antidiabetic drugs with the National Guide recommendations.",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine, Diabetes in Serbia: trends in antidiabetic drug consumption from 2012 to 2021",
volume = "73",
number = "Suppl. 4",
pages = "S51-S52",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5352"
}
Jovanović, A., Kundalić, A., Miladinović, B., Džodić, P., Catić-Đorđević, A., Krajnović, D.,& Tadić, I.. (2023). Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(Suppl. 4), S51-S52.
https://hdl.handle.net/21.15107/rcub_farfar_5352
Jovanović A, Kundalić A, Miladinović B, Džodić P, Catić-Đorđević A, Krajnović D, Tadić I. Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine. in Arhiv za farmaciju. 2023;73(Suppl. 4):S51-S52.
https://hdl.handle.net/21.15107/rcub_farfar_5352 .
Jovanović, Aleksandar, Kundalić, Ana, Miladinović, Bojana, Džodić, Predrag, Catić-Đorđević, Aleksandra, Krajnović, Dušanka, Tadić, Ivana, "Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine" in Arhiv za farmaciju, 73, no. Suppl. 4 (2023):S51-S52,
https://hdl.handle.net/21.15107/rcub_farfar_5352 .

Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma

Džodić, Predrag; Živanović, Ljiljana; Protić, Ana; Ivanović, Ivana; Veličković-Radovanović, Radmila; Spasić, Mirjana; Lukić, Stevo; Živanović, Slavoljub

(Srpsko hemijsko društvo, Beograd, 2012)

TY  - JOUR
AU  - Džodić, Predrag
AU  - Živanović, Ljiljana
AU  - Protić, Ana
AU  - Ivanović, Ivana
AU  - Veličković-Radovanović, Radmila
AU  - Spasić, Mirjana
AU  - Lukić, Stevo
AU  - Živanović, Slavoljub
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1823
AB  - A solid phase extraction-HPLC method has been developed and validated for the rapid analysis of carbamazepine and its two metabolites, carbamazepine epoxide and carbamazepine trans-diol, in human plasma. The analysis was performed using a C18 Bakerbond-BDC analytical column (250 mm×4.6 mm i.d., particle size 5 μm). The optimal conditions for the separation were established with the mobile phase acetonitrile - 10 mM phosphate buffer, pH 7.0 (30:70, v/v) at a flow rate of 1.5 mL min-1 and temperature of 35°C, with UV detection at 210 nm. The total run time was about 8 minutes. The SPE procedure for the extraction of the analytes from a plasma sample was developed using Oasis HLB cartridges and subsequently, the eluate was injected into the HPLC system for analysis. Afterwards, the SPE-HPLC method was subjected to validation. Linearity was obtained over the concentration range of 0.2-25 μg mL-1 for carbamazepine, carbamazepine epoxide and carbamazepine trans-diol, with correlation coefficients higher than 0.995. The method showed good intra-day and inter-day precision with a relative standard deviation below 7.96 %, while the accuracy ranged from 92.09 to 108.5 % for all analytes. Finally, the method was successfully applied to the analysis of the plasma samples of epileptic patients in mono- and polytherapy.
AB  - SPE-HPLC metoda je razvijena i validirana u cilju brzog analiziranja karbamazepina i metabolita karbamazepin epoksida i karbamazepin trans-diola u humanoj plazmi. C18 Bakerbond-BDC analitička kolona (250 mm x 4,6 mm; 5 μm) je korišćena radi izvođenja analize. Optimalni uslovi za hromatografsko razdvajanje su mobilna faza acetonitril - 10 mM fosfatni pufer, pH 7,0 (30:70, v/v), protok od 1,5 ml min-1, temperatura 35°C i detekcija na 210 nm. Ukupno trajanje hromatografskog rana iznosi oko 8 min. SPE procedura za ekstrakciju analita iz uzoraka plazme je razvijena uz korišćenje Oasis HLB ketridža nakon čega se eluat injektuje u HPLC sistem radi analiziranja. Zatim je izvršena validacija SPE-HPLC metode. Linearnost je potvrđena u koncentracionom opsegu 0,2-25 μg/ml za karbamazepin, karbamazepin epoksid i karbamazepin trans-diol sa vrednošću korelacionih koeficijenata višom od 0,995. Preciznost metode u toku jednog i u toku više dana je dobra sa relativnom standardnom devijacijom nižom od 7,96 %, dok tačnost metode obuhvata vrednosti u opsegu od 92,09 do 108,5 % za sve analite. Na kraju je metoda uspešno primenjena u cilju analiziranja uzoraka plazme pacijenata obolelih od epilepsije na monoterapiji i politerapiji.
PB  - Srpsko hemijsko društvo, Beograd
T2  - Journal of the Serbian Chemical Society
T1  - Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma
T1  - Razvoj i validacija spe-HPLC metode za određivanje karbamazepina i metabolita karbamazepin epoksida i karbamazepin trans-diola u plazmi
VL  - 77
IS  - 10
SP  - 1423
EP  - 1436
DO  - 10.2298/JSC120106084D
ER  - 
@article{
author = "Džodić, Predrag and Živanović, Ljiljana and Protić, Ana and Ivanović, Ivana and Veličković-Radovanović, Radmila and Spasić, Mirjana and Lukić, Stevo and Živanović, Slavoljub",
year = "2012",
abstract = "A solid phase extraction-HPLC method has been developed and validated for the rapid analysis of carbamazepine and its two metabolites, carbamazepine epoxide and carbamazepine trans-diol, in human plasma. The analysis was performed using a C18 Bakerbond-BDC analytical column (250 mm×4.6 mm i.d., particle size 5 μm). The optimal conditions for the separation were established with the mobile phase acetonitrile - 10 mM phosphate buffer, pH 7.0 (30:70, v/v) at a flow rate of 1.5 mL min-1 and temperature of 35°C, with UV detection at 210 nm. The total run time was about 8 minutes. The SPE procedure for the extraction of the analytes from a plasma sample was developed using Oasis HLB cartridges and subsequently, the eluate was injected into the HPLC system for analysis. Afterwards, the SPE-HPLC method was subjected to validation. Linearity was obtained over the concentration range of 0.2-25 μg mL-1 for carbamazepine, carbamazepine epoxide and carbamazepine trans-diol, with correlation coefficients higher than 0.995. The method showed good intra-day and inter-day precision with a relative standard deviation below 7.96 %, while the accuracy ranged from 92.09 to 108.5 % for all analytes. Finally, the method was successfully applied to the analysis of the plasma samples of epileptic patients in mono- and polytherapy., SPE-HPLC metoda je razvijena i validirana u cilju brzog analiziranja karbamazepina i metabolita karbamazepin epoksida i karbamazepin trans-diola u humanoj plazmi. C18 Bakerbond-BDC analitička kolona (250 mm x 4,6 mm; 5 μm) je korišćena radi izvođenja analize. Optimalni uslovi za hromatografsko razdvajanje su mobilna faza acetonitril - 10 mM fosfatni pufer, pH 7,0 (30:70, v/v), protok od 1,5 ml min-1, temperatura 35°C i detekcija na 210 nm. Ukupno trajanje hromatografskog rana iznosi oko 8 min. SPE procedura za ekstrakciju analita iz uzoraka plazme je razvijena uz korišćenje Oasis HLB ketridža nakon čega se eluat injektuje u HPLC sistem radi analiziranja. Zatim je izvršena validacija SPE-HPLC metode. Linearnost je potvrđena u koncentracionom opsegu 0,2-25 μg/ml za karbamazepin, karbamazepin epoksid i karbamazepin trans-diol sa vrednošću korelacionih koeficijenata višom od 0,995. Preciznost metode u toku jednog i u toku više dana je dobra sa relativnom standardnom devijacijom nižom od 7,96 %, dok tačnost metode obuhvata vrednosti u opsegu od 92,09 do 108,5 % za sve analite. Na kraju je metoda uspešno primenjena u cilju analiziranja uzoraka plazme pacijenata obolelih od epilepsije na monoterapiji i politerapiji.",
publisher = "Srpsko hemijsko društvo, Beograd",
journal = "Journal of the Serbian Chemical Society",
title = "Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma, Razvoj i validacija spe-HPLC metode za određivanje karbamazepina i metabolita karbamazepin epoksida i karbamazepin trans-diola u plazmi",
volume = "77",
number = "10",
pages = "1423-1436",
doi = "10.2298/JSC120106084D"
}
Džodić, P., Živanović, L., Protić, A., Ivanović, I., Veličković-Radovanović, R., Spasić, M., Lukić, S.,& Živanović, S.. (2012). Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma. in Journal of the Serbian Chemical Society
Srpsko hemijsko društvo, Beograd., 77(10), 1423-1436.
https://doi.org/10.2298/JSC120106084D
Džodić P, Živanović L, Protić A, Ivanović I, Veličković-Radovanović R, Spasić M, Lukić S, Živanović S. Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma. in Journal of the Serbian Chemical Society. 2012;77(10):1423-1436.
doi:10.2298/JSC120106084D .
Džodić, Predrag, Živanović, Ljiljana, Protić, Ana, Ivanović, Ivana, Veličković-Radovanović, Radmila, Spasić, Mirjana, Lukić, Stevo, Živanović, Slavoljub, "Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma" in Journal of the Serbian Chemical Society, 77, no. 10 (2012):1423-1436,
https://doi.org/10.2298/JSC120106084D . .
9
10
12

Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography

Džodić, Predrag; Živanović, Ljiljana; Protić, Ana; Zečević, Mira; Jocić, Biljana

(AOAC Int, Gaithersburg, 2010)

TY  - JOUR
AU  - Džodić, Predrag
AU  - Živanović, Ljiljana
AU  - Protić, Ana
AU  - Zečević, Mira
AU  - Jocić, Biljana
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1341
AB  - An accurate and precise RP-HPLC method was developed and validated for the determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in a tablet formulation with fluphenazine as an internal standard. Buffer methanol (50 + 50, v/v) was used as the mobile phase. During validation, specificity, linearity, precision, accuracy, LOD, LOQ, and robustness of the method were tested. The method was proven to be specific against placebo interference. Linearity was evaluated over the concentration range of 100-500, 0.05-0.25, and 0.1-0.5 mu g/mL, and the r values were 0.9994, 0.9997, and 0.9979 for carbamazepine, iminostilbene, and iminodibenzyl, respectively. Intraday precision of the method was good, and RSD was below 2% for all analytes. The accuracy of the method ranged from 100.69 to 102.10, 99.76 to 102.66, and 99.26 to 100.08% for carbamazepine, iminostilbene, and iminodibenzyl, respectively. LOD was 0.0125, 0.025, and 0.05 mu g/mL and LOQ was 0.05, 0.05, and 0.1 mu g/mL for carbamazepine, iminostilbene, and iminodibenzyl, respectively. Robustness of the method was proven by using a chemometric approach. The method was successfully applied to the analysis of commercially available carbamazepine tablets and showed good repeatability, with RSD below 2%.
PB  - AOAC Int, Gaithersburg
T2  - Journal of AOAC International
T1  - Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography
VL  - 93
IS  - 4
SP  - 1059
EP  - 1068
DO  - 10.1093/jaoac/93.4.1059
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1341
ER  - 
@article{
author = "Džodić, Predrag and Živanović, Ljiljana and Protić, Ana and Zečević, Mira and Jocić, Biljana",
year = "2010",
abstract = "An accurate and precise RP-HPLC method was developed and validated for the determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in a tablet formulation with fluphenazine as an internal standard. Buffer methanol (50 + 50, v/v) was used as the mobile phase. During validation, specificity, linearity, precision, accuracy, LOD, LOQ, and robustness of the method were tested. The method was proven to be specific against placebo interference. Linearity was evaluated over the concentration range of 100-500, 0.05-0.25, and 0.1-0.5 mu g/mL, and the r values were 0.9994, 0.9997, and 0.9979 for carbamazepine, iminostilbene, and iminodibenzyl, respectively. Intraday precision of the method was good, and RSD was below 2% for all analytes. The accuracy of the method ranged from 100.69 to 102.10, 99.76 to 102.66, and 99.26 to 100.08% for carbamazepine, iminostilbene, and iminodibenzyl, respectively. LOD was 0.0125, 0.025, and 0.05 mu g/mL and LOQ was 0.05, 0.05, and 0.1 mu g/mL for carbamazepine, iminostilbene, and iminodibenzyl, respectively. Robustness of the method was proven by using a chemometric approach. The method was successfully applied to the analysis of commercially available carbamazepine tablets and showed good repeatability, with RSD below 2%.",
publisher = "AOAC Int, Gaithersburg",
journal = "Journal of AOAC International",
title = "Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography",
volume = "93",
number = "4",
pages = "1059-1068",
doi = "10.1093/jaoac/93.4.1059",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1341"
}
Džodić, P., Živanović, L., Protić, A., Zečević, M.,& Jocić, B.. (2010). Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography. in Journal of AOAC International
AOAC Int, Gaithersburg., 93(4), 1059-1068.
https://doi.org/10.1093/jaoac/93.4.1059
https://hdl.handle.net/21.15107/rcub_farfar_1341
Džodić P, Živanović L, Protić A, Zečević M, Jocić B. Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography. in Journal of AOAC International. 2010;93(4):1059-1068.
doi:10.1093/jaoac/93.4.1059
https://hdl.handle.net/21.15107/rcub_farfar_1341 .
Džodić, Predrag, Živanović, Ljiljana, Protić, Ana, Zečević, Mira, Jocić, Biljana, "Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form by Column High-Performance Liquid Chromatography" in Journal of AOAC International, 93, no. 4 (2010):1059-1068,
https://doi.org/10.1093/jaoac/93.4.1059 .,
https://hdl.handle.net/21.15107/rcub_farfar_1341 .
8
9

Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form

Džodić, Predrag; Živanović, Ljiljana; Protić, Ana; Zečević, Mira; Jocić, Biljana

(Springer Heidelberg, Heidelberg, 2009)

TY  - JOUR
AU  - Džodić, Predrag
AU  - Živanović, Ljiljana
AU  - Protić, Ana
AU  - Zečević, Mira
AU  - Jocić, Biljana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1214
AB  - A chemometrical approach was applied to develop a reversed-phase liquid chromatographic method for simultaneous determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in solid dosage form. According to contemporary literature, no method was developed for simultaneous determination of carbamazepine and these impurities by chemometrical approach. The fractional factorial design was used for selection of variables significantly influencing the chromatographic separation of the investigated substances. The investigated variables were: temperature of the column, the percentage of organic modifier, the acetate buffer concentration and pH of water phase. The first three variables were proved to be significant and were optimized by face centered, central composite design. Investigation was performed using C18 XBridge Shield analytical column (50 mm x 4.6 mm i.d., particle size 3.5 A mu m). The optimal conditions for the separation were established with the mobile phase composition of methanol-10 mM acetate buffer (pH adjusted to 2.21 with glacial acetic acid) (50:50, v/v) at a flow rate of 1.5 mL min(-1), 25 A degrees C column temperature and detection at 260 nm. Total analysis time was shortened to about 8 min. Finally, the method was successfully validated and subsequently applied to the analysis of commercially available carbamazepine tablets.
PB  - Springer Heidelberg, Heidelberg
T2  - Chromatographia
T1  - Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form
VL  - 70
IS  - 9-10
SP  - 1343
EP  - 1351
DO  - 10.1365/s10337-009-1322-6
ER  - 
@article{
author = "Džodić, Predrag and Živanović, Ljiljana and Protić, Ana and Zečević, Mira and Jocić, Biljana",
year = "2009",
abstract = "A chemometrical approach was applied to develop a reversed-phase liquid chromatographic method for simultaneous determination of carbamazepine and its impurities iminostilbene and iminodibenzyl in solid dosage form. According to contemporary literature, no method was developed for simultaneous determination of carbamazepine and these impurities by chemometrical approach. The fractional factorial design was used for selection of variables significantly influencing the chromatographic separation of the investigated substances. The investigated variables were: temperature of the column, the percentage of organic modifier, the acetate buffer concentration and pH of water phase. The first three variables were proved to be significant and were optimized by face centered, central composite design. Investigation was performed using C18 XBridge Shield analytical column (50 mm x 4.6 mm i.d., particle size 3.5 A mu m). The optimal conditions for the separation were established with the mobile phase composition of methanol-10 mM acetate buffer (pH adjusted to 2.21 with glacial acetic acid) (50:50, v/v) at a flow rate of 1.5 mL min(-1), 25 A degrees C column temperature and detection at 260 nm. Total analysis time was shortened to about 8 min. Finally, the method was successfully validated and subsequently applied to the analysis of commercially available carbamazepine tablets.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Chromatographia",
title = "Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form",
volume = "70",
number = "9-10",
pages = "1343-1351",
doi = "10.1365/s10337-009-1322-6"
}
Džodić, P., Živanović, L., Protić, A., Zečević, M.,& Jocić, B.. (2009). Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form. in Chromatographia
Springer Heidelberg, Heidelberg., 70(9-10), 1343-1351.
https://doi.org/10.1365/s10337-009-1322-6
Džodić P, Živanović L, Protić A, Zečević M, Jocić B. Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form. in Chromatographia. 2009;70(9-10):1343-1351.
doi:10.1365/s10337-009-1322-6 .
Džodić, Predrag, Živanović, Ljiljana, Protić, Ana, Zečević, Mira, Jocić, Biljana, "Chemometrically Assisted Development and Validation of LC for Simultaneous Determination of Carbamazepine and Its Impurities Iminostilbene and Iminodibenzyl in Solid Dosage Form" in Chromatographia, 70, no. 9-10 (2009):1343-1351,
https://doi.org/10.1365/s10337-009-1322-6 . .
9
8
9